IRS-1 gene polymorphism and DNA damage in pregnant women with diabetes or mild gestational hyperglycemia

Diabetology & Metabolic Syndrome

Marilza V C Rudge²  Iracema M P Calderon²  Glilciane Morceli²  Paula H O Lima²  João Paulo C Marcondes¹  Daisy M F Salvadori¹  Débora C Damasceno²  Rafael B Gelaleti² 

[1] Department of Pathology, Laboratory of Toxigenomics and Nutrigenomics, Botucatu Medical School, Unesp_Univ Estadual Paulista, Botucatu, Brazil;Department of Gynecology and Obstetrics, Botucatu Medical School, Unesp_Univ Estadual Paulista, Laboratory of Experimental Research in Gynecology and Obstetrics, Distrito de Rubião Júnior s/n, CEP. 18618.000, Botucatu, São Paulo, Brazil

关键词: DNA damage;    Polymorphism;    Newborn;    Pregnancy;    Mild gestational hyperglycemia;    Diabetes;   

Others  :  1174870
DOI  :  10.1186/s13098-015-0026-3

 received in 2014-10-14, accepted in 2015-03-19,  发布年份 2015

【 摘 要 】

Background

Pregnant women with mild gestational hyperglycemia present a high risk for hypertension and obesity, and appear to reproduce the model of metabolic syndrome in pregnancy, including hyperinsulinemia and insulin resistance. Diabetic patients have a higher frequency of the IRS-1 Gly972Arg variant and this polymorphism is directly related to insulin resistance and subsequent hyperglycemia. In diabetes, hyperglycemia and other associated factors generate reactive oxygen species that increase DNA damage. The aims of this study were to evaluate the presence of the IRS-1 Arg972 polymorphism in pregnant women with diabetes or mild gestational hyperglycemia, and in their newborns. Additionally, we evaluated the level of primary DNA damage in lymphocytes of Brazilian pregnant women and the relationship between the amount of genetic damage and presence of the polymorphism.

Methods

A based on the oral glucose tolerance test (OGTT) results and on glycemic profiles (GP), as follows: non-diabetic group, mild gestational hyperglycemia (MGH) and diabetic group. Eighty-five newborns were included in the study. Maternal peripheral blood samples and umbilical cord blood samples (5–10 mL) were collected for genotyping by PCR-RFLP and for comet assays.

Results

The prevalence of genotype Gly/Arg in pregnant women groups was not statistically significant. In newborns, the frequency of Gly/Arg was significantly higher in the MGH and diabetic groups than in the non-diabetic group. Taken together, groups IIA and IIB (IIA + IIB; diabetes) presented lower amounts of DNA damage than the non-diabetic group (p = 0.064). No significant association was detected between genetic damage and the presence of the Arg972 genotype in pregnant women.

Conclusion

The polymorphism was more prevalent in newborns of diabetic and MGH women. We believe that it is necessary to increase the number of subjects to be examined in order to better determine the biological role of the Arg972 polymorphism in these patients. Despite being classified as low-risk, pregnant women with mild gestational hyperglycemia characterize a population of maternal and perinatal adverse outcomes, and that, together with their newborns, require better monitoring by professionals and health services.

【 授权许可】

   
2015 Gelaleti et al.; licensee BioMed Central.

【 参考文献 】

• [1]HAPO Study Cooperative Research Group: Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: associations with neonatal anthropometrics Diabetes 2009, 58(2):453-9.
• [2]Rudge MVC, Calderon IMP, Ramos MD, Abbade JF, Rugolo LMSS: Perinatal outcome of pregnancies complicated by diabetes and by maternal daily hyperglycemia not related to diabetes. A retrospective 10 year analysis. Gynecol Obst Invest 2000, 50:108-12.
• [3]Negrato CA, Jovanovic L, Tambascia MA, Calderon IMP, Geloneze B, Dias A, et al.: Mild gestational hyperglycaemia as a risk factor for metabolic syndrome in pregnancy and adverse perinatal outcomes. Diabetes Metab Res Rev 2008, 24(4):324-30.
• [4]Silva MRG, Calderon IMP, Gonçalves LC, Aragon FF, Padovani CR, Pimenta WP: Ocorrência de diabetes melito em mulheres com hiperglicemia em gestação prévia. Rev Saude Publica 2003, 37:345-50.
• [5]Watanabe RM, Valle T, Hauser ER, Ghosh S, Eriksson J, Kohtamäki K, et al.: The Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Hum Hered 1999, 49:159-68.
• [6]Carvalheira JBC, Zecchin HG, Saad MJ. Vias de Sinalização da Insulina. Arq Bras Endocrinol Metab. 2002;vol46 n4.
• [7]Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al.: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010, 42:105-16.
• [8]Saxena R, Hivert M, Langenberg C, Tanaka T, Pankow J, Lyssenko V, et al.: Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010, 42(2):142-8.
• [9]Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proença C, et al.: Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet 2009, 41:1110-5.
• [10]Porzio O, Federici M, Hribal M: The Arg972 amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic ß cells. J Clin Invest 1999, 104:357-64.
• [11]Tok EC, Ertunc D, Bilgin O, Erdal EM, Kaplanoglu M, Dilek S: Association of insulin receptor substrate-1 G972R variant with baseline characteristics of the patients with gestational diabetes mellitus. Am J Obstet Gynecol 2006, 194(3):868-72.
• [12]Gelaleti RB, Lima PHO, Damasceno DC, Calderon IMP, Rudge MVC. Diabetes e o Polimorfismo Gly972Arg - Atualização Bibliográfica. Diabetes Clínica. 2011. v04p204/04-209.
• [13]Vergotine Z, Kengne AP, Erasmus RT, Matsha TE: No evidence for association of insulin receptor substrate-1 Gly972Arg variant with type 2 diabetes mellitus in a mixed-ancestry population of South Africa. S Afr Med J 2014, 104(6):420-3.
• [14]Wright E Jr, Scism-Bacon JL, Glass LC: Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 2006, 60(3):308-14.
• [15]Dinçer Y, Akçay T, Ilkova H, Alademir Z, Ozbay G: DNA damage and antioxidant defense in peripheral leukocytes of patients with type 1 diabetes mellitus. Mutat Res 2003, 527:49-55.
• [16]Pitozzi V, Giovannelli L, Bardini G, Rotella CM, Dolara P: Oxidative DNA damage in peripheral blood cells in type 2 diabetes mellitus: higher vulnerability of polymorphonuclear leukocytes. Mutat Res 2003, 28:129-33.
• [17]Zengi A, Ercan G, Caglayan O, Tamsel S, Karadeniz M, Simsir I, et al.: Increased oxidative DNA damage in lean normoglycemic offspring of type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2011, 119:467-71.
• [18]Carpenter MW, Coustan DR: Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982, 144(7):768-73.
• [19]Gilmer MDG, Beard RW, Brooke FM, Oakley NW: Carbohydrate metabolism in pregnancy. Part I. Diurnal plasma glucose profi le in normal and diabetic women. Br Med J 1975, 3(5980):399-402.
• [20]Rudge MVC, Calderon IMP, Ramos MD, Maestá I, Souza LMS, Peraçoli JC: Perspectiva perinatal decorrente do rígido controle pré-natal em gestações complicadas pelo diabete. RBGO 1995, 17:26-32.
• [21]American Diabetes Association (ADA): Diagnosis and classification of diabete mellitus Diabetes Care 2010, 33 Suppl 1:S62-9.
• [22]Salazar LA, Hirata MH, Cavalli SS, Machado MO, Hirata RD: Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin Chem 1998, 44:1748-50.
• [23]Almind K, Bjørbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O: Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 1993, 342(8875):828-32.
• [24]Collins AR, Raslová K, Smorovská MP, Petrovská H, Ondrusová A, Vohnout B, et al.: DNA damage in diabetes: correlation with a clinical marker. Free Rad Biol Med 1998, 25:373-7.
• [25]Blasiak J, Arabski M, Krupa R, Wozniak K, Zadrozny M, Zurawska M, et al.: DNA damage and repair in type 2 diabetes mellitus. Mutat Res 2004, 554:297-304.
• [26]Orkunoglu SFE, Mergen H, Bolu E, Ozata M: Molecular scanning for mutations in the insulin receptor substrate (Irs-1) gene in Turkish with type 2 diabetes mellitus. Endocr J 2005, 52(5):593-8.
• [27]Jellema A, Mensink RP, Kromhout D, Saris WH, Feskens EJ: Metabolic risk markers in an overweight and normal weight population with oversampling of carriers of the IRS-1 972Arg-variant. Atherosclerosis 2003, 171(1):75-81.
• [28]Fallucca F, Dalfrà MG, Sciullo E, Masin M, Buongiorno AM, Napoli A, et al.: Polymorphisms of insulin receptor substrate 1 and beta3-adrenergic receptor genes in gestational diabetes and normal pregnancy. Metabolism 2006, 55(11):1451-6.
• [29]Negrato CA, Jovanovic L, Rafacho A, Tambascia MA, Geloneze B, Dias A, et al.: Association between different levels of dysglycemia and metabolic syndrome in pregnancy. Diabetol Metab Syndr 2009, 1(1):3. BioMed Central Full Text
• [30]Rett K, Koch M, Volk A, Maerker E, Jacob S, Haering HU, et al.: Codon 972 polymorphism of the IRS-1 gene is prevalent in offspring of subjects with type 2 diabetes without determining clamp-derived insulin action. Diabetes 1998, 47(Suppl. 1):393a. Abstr
• [31]Zhang Y, Wat N, Stratton IM, Warren-Perry MG, Orho M, Groop L, et al.: UKPDS 19: heterogeneity in NIDDM: separate contributions of IRS-1 and b3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. Diabetologia 1996, 39:1505-11.
• [32]Shirakami A, Toyonaga T, Tsuruzoe K, Shirotani T, Matsumoto K, Yoshizato K, et al.: Heterozygous knockout of the IRS-1 gene in mice enhances obesity-linked insulin resistance: a possible model for the development of type 2 diabetes. J Endocrinol 2002, 174(2):309-19.
• [33]Mattar R, Torloni MR, Betrán AP, Merialdi M: Obesity and pregnancy. Rev Bras Ginecol Obstet 2009, 31:107-10.
• [34]Karbownik-Lewinska M, Szosland J, Kokoszko-Bilska A, Stępniak J, Zasada K, Gesing A, et al.: Direct contribution of obesity to oxidative damage to macromolecules. Neuro Endocrinol Lett 2012, 33(4):453-61.
• [35]Wayhs CA, Manfredini V, Sitta A, Deon M, Ribas GS, Vanzin CS, et al.: Effects of insulin and clonazepam on DNA damage in diabetic rats submitted to the forced swimming test. Mutat Res 2010, 703(2):187-90.
• [36]Wang JS, Huang YH: Effects of exercise intensity on lymphocyte apoptosis induced by oxidative stress in men. Eur J Appl Physiol 2005, 95(4):290-7.
• [37]Kim KS, Paik IY, Woo JH, Kang BY: The effect of training type on oxidative DNA damage and antioxidant capacity during three-dimensional space exercise. Med Princ Pract 2010, 19(2):133-41.
• [38]Siu PM, Pei XM, Teng BT, Benzie IF, Ying M, Wong SH: Habitual exercise increases resistance of lymphocytes to oxidant-induced DNA damage by upregulating expression of antioxidant and DNA repairing enzymes. Exp Physiol 2011, 96(9):889-906.
• [39]Staruchová M, Volková K, Lajdová A, Misl’anová C, Collins A, Wsólová L, et al.: Importance of diet in protection against oxidative damage. Neuro Endocrinol Lett 2006, 27(Suppl 2):112-5.
• [40]Ochi H, Sakai K: Oxidative stress profile: OSP. Rinsho Byori 2003, 51(2):115-25.
• [41]Simońska-Cichocka E, Gumprecht J, Zychma M, Witkowska A, Misiołek H, Slawska H, et al.: The polymorphism in insulin receptor substrate-1 gene and birth weight in neonates at term. Endokrynol Pol 2008, 59(3):212-6.
• [42]Bezerra RMN, Castro V, Sales T, PassiniJr R, Marba STM, Saad ST, et al.: The Gly972Arg polymorphism in Insulin receptor substrate-1 is associated with decreased birth weight in a population-based sample of Brazilian newborns. Diabetes Care 2002, 25(3):550-3.
• [43]Clausen JO, Hansen T, Bjørbaek C, Echwald SM, Urhammer SA, Rasmussen S, et al.: Insulin resistance: interaction between obesity and a common variant of insulin receptor substrate-1. Lancet 1995, 346:397-402.
• [44]Imai Y, Fusco A, Suzuki Y, Lesniak MA, D’Alfonso R, Sesti G, et al.: Variant sequences of insulin receptor substrate-1 in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994, 79:1655-8.
• [45]Le Fur S, Le Stunff C, Bougnères P: Increased insulin resistance in obese children who have both 972 IRS-1 and 1057 IRS-2 polymorphisms. Diabetes 2002, 51(l3):304-7.
• [46]Rudge MVC: Perfil glicêmico e teste de tolerância oral à glicose no diagnóstico do diabete na gravidez. (Livre-Docência). Faculdade de Medicina, Universidade Estadual Paulista, Botucatu; 1983.
• [47]Rudge MVC, Calderon IMP, Ramos MD, Brasil MAM, Rugolo LMSS, Bossolan G, et al.: Hiperglicemia materna diária diagnosticada pelo perfil glicêmico: um problema de saúde pública materno e perinatal. Rev Bras Ginecol Obstet 2005, 27:691-7.